Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes
PHASE3UnknownINTERVENTIONAL
Enrollment
230
Participants
Timeline
Start Date
June 30, 2014
Primary Completion Date
September 30, 2016
Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG
Gemigliptin/Glimepiride combination
Trial Locations (1)
Unknown
The Catholic University of Korea Seoul St. Mary's Hospital, Seoul
NCT02089126 - Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter